EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intravenous fluid therapy and hospital outcomes for vaso‐occlusive episodes in children, adolescents, and young adults with sickle cell disease

Abraham Haimed iD, Rebecca Weiss, Soyang Kwon, Rukhmi Bhat iD, Sherif M Badawy iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30781 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Abraham Haimed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Divison of Hematology, Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Acute Chest Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While intravenous fluid (IVF) therapy in patients with sickle cell disease (SCD) admitted for a vaso‐occlusive episode (VOE) can help reduce red blood cell sickling, clinical practice varies across institutions. We examined the relationship between IVF therapy and hospital length of stay (HLOS), as well as adverse events, such as acute chest syndrome (ACS), pediatric intensive care unit (PICU) transfer, and 28‐day re‐admission.

Methods

This is a single‐center retrospective analysis of SCD VOE hospitalizations between January 2015 and April 2020. Patients with SCD, age 0–30, with consecutive hospitalizations for VOE were included. For the first 3 days of each admission, an “IVF ratio” was calculated by dividing actual IVF rate administered by weight‐based maintenance IVF (mIVF) rate.

Results

A total of 617 hospitalizations for 161 patients were included. Mean HLOS was 5.7 days, (SD 3.9), and mean IVF volume over the first 3 days of admission was 139.6 mL/kg/day (SD 57.8). Multivariate analysis showed that for each additional 0.5 times the mIVF rate, HLOS increased by 0.53 day ( p < .001; 95% confidence interval [CI]: 0.609–0.989), but there was no significant association between IVF therapy and adverse events. History of chronic pain was associated with increased odds of re‐admission (OR 6.4; 95% CI: 3.93–10.52).

Conclusions

Despite the theoretical potential for IVF therapy to slow down the sickling process, our findings suggest that increased IVF therapy was associated with prolonged HLOS, which places a burden on patients, families, and the health system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellAcute Chest SyndromeChildHumansAdolescentYoung AdultInfant, NewbornInfantChild, PreschoolAdultRetrospective StudiesFluid TherapyHospitals

Stichwörter der Autor:innen

intravenous fluidssickle cellvaso-occlusive episodes

Autor:innen und Institutionen

  • Divison of Hematology, Oncology and Stem Cell Transplantation, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Stanley Manne Children's Research Institute, Chicago, Illinois, USA.

ORCID-Profile: Abraham Haimed, Rukhmi Bhat, Sherif M Badawy

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Haimed, A., Weiss, R., Kwon, S., Bhat, R., & Badawy, S. M. (2024). Intravenous fluid therapy and hospital outcomes for vaso‐occlusive episodes in children, adolescents, and young adults with sickle cell disease. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30781

Vancouver

Haimed A, Weiss R, Kwon S, Bhat R, Badawy SM. Intravenous fluid therapy and hospital outcomes for vaso‐occlusive episodes in children, adolescents, and young adults with sickle cell disease. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30781

BibTeX
@article{Haimed2024,
  author = {Haimed, Abraham and Weiss, Rebecca and Kwon, Soyang and Bhat, Rukhmi and Badawy, Sherif M},
  title = {Intravenous fluid therapy and hospital outcomes for vaso‐occlusive episodes in children, adolescents, and young adults with sickle cell disease},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30781}
}
Kostenlos starten →